Q2 2025 EPS Estimates for Haemonetics Co. (NYSE:HAE) Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for Haemonetics in a report released on Monday, October 7th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $1.09 per share for the quarter, down from their previous forecast of $1.10. The consensus estimate for Haemonetics’ current full-year earnings is $4.57 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2026 earnings at $1.28 EPS and FY2026 earnings at $5.15 EPS.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million for the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.05 earnings per share.

Other research analysts have also recently issued reports about the company. BTIG Research began coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target for the company. CL King began coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. Citigroup dropped their price objective on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Barrington Research restated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research note on Monday, September 23rd. Finally, Bank of America started coverage on Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $106.14.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $74.45 on Wednesday. The stock has a 50 day moving average price of $76.95 and a 200 day moving average price of $83.98. Haemonetics has a 52 week low of $70.74 and a 52 week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. The stock has a market capitalization of $3.79 billion, a PE ratio of 32.51, a price-to-earnings-growth ratio of 1.19 and a beta of 0.30.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its holdings in shares of Haemonetics by 3.3% in the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier’s stock valued at $304,000 after purchasing an additional 117 shares in the last quarter. QRG Capital Management Inc. boosted its holdings in shares of Haemonetics by 6.9% in the 2nd quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier’s stock valued at $333,000 after purchasing an additional 260 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Haemonetics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier’s stock valued at $1,176,000 after purchasing an additional 272 shares in the last quarter. State of Michigan Retirement System boosted its holdings in shares of Haemonetics by 2.5% in the 1st quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier’s stock valued at $1,065,000 after purchasing an additional 300 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its holdings in shares of Haemonetics by 2.1% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 18,300 shares of the medical instruments supplier’s stock valued at $1,562,000 after purchasing an additional 374 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the transaction, the insider now owns 18,196 shares in the company, valued at $1,658,565.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.80% of the company’s stock.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.